Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04865679 · ClinicalTrials.gov registry record · NA

Tolerability and Feasibility Pilot Clinical Study of a Large-Diameter Nerve Cap for Protecting and Preserving Terminated Nerve Ends

A NA study of Amputation and Symptomatic Neuroma, sponsored by Axogen Corporation.

Active
Registry status
NA
Development phase
15
Enrollment target
2
Study locations

NCT04865679: Active NA study of Amputation and Symptomatic Neuroma, sponsored by Axogen Corporation.

NCT04865679 is a NA study of Amputation and Symptomatic Neuroma that is active but no longer recruiting, run by Axogen Corporation. The registered enrollment target is 15 participants, below the 133-participant average among 65 other Amputation trials with a reported enrollment target (89% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04865679, a NA study of Amputation and Symptomatic Neuroma, is active but no longer recruiting, sponsored by Axogen Corporation.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
15 participants
Enrollment target
2
Study locations

Study Summary

This pilot study evaluates the tolerability and feasibility of the Axoguard Large-Diameter Nerve Cap (sizes 5-7 mm) for protecting and preserving terminated nerve endings after limb trauma or amputation when immediate attention to the nerve injuries is not possible.

Primary Outcome

The primary safety endpoint will monitor the nature and incidence of AE's, SAE's and/or UADE's associated with an unplanned revision procedure prior to the planned Targeted Muscle Reinnervation (TMR) or Regenerative Peripheral Nerve Interface (RPNI) starting from implantation (operative day) through 15 months depending on whether or not the subject undergoes the secondary TMR or RPNI procedure.

Interventions

  • DEVICE Axoguard Nerve Cap®

Study Locations (2)

Massachusetts

  • Massachusetts General Hospital - Boston

Texas

  • Texas Tech University, Health Science Center - Lubbock

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2022-03-02
Est. Completion 2026-12
Phase NA
Axogen Corporation

10 total trials

What the registry record for NCT04865679 still lists

NCT04865679 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 133-participant average among 65 other Amputation trials with a reported enrollment target (89% lower).

The record links to 3 conditions, with Amputation appearing as the primary indexed condition, and to 1 intervention - of which Axoguard Nerve Cap® is the first listed.

NCT04865679 reports a single indexed study location in Massachusetts, Texas.

Frequently Asked Questions

What is clinical trial NCT04865679 about?

NCT04865679 is a clinical study titled "Tolerability and Feasibility Pilot Clinical Study of a Large-Diameter Nerve Cap for Protecting and Preserving Terminated Nerve Ends". This pilot study evaluates the tolerability and feasibility of the Axoguard Large-Diameter Nerve Cap (sizes 5-7 mm) for protecting and preserving terminated nerve endings after limb trauma or amputation when immediate attention to the nerve injuries is not possible.

What is the current status of trial NCT04865679?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 15 participants. The study started on 2022-03-02. Estimated completion is 2026-12.

What conditions does trial NCT04865679 study?

This clinical trial studies the following conditions: Amputation, Symptomatic Neuroma, Chronic Nerve Pain.

What interventions are being tested in trial NCT04865679?

The interventions under investigation include: Axoguard Nerve Cap® (DEVICE).

Who is sponsoring clinical trial NCT04865679?

This trial is sponsored by Axogen Corporation, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04865679 being conducted?

This trial has 2 study locations across Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Amputation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04865679's enrollment target sits among peer trials

15 44th of 65 higher than 20 of 65 other Amputation trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Amputation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01889381 · 15 participants · Phase 2

    Human Craniomaxillofacial Allotransplantation

  • NCT02530073 · 15 participants · NA

    Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH

  • NCT02535936 · 15 participants · NA

    Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy

  • NCT02918474 · 15 participants · NA

    Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04865679, the US trial registry maintained by the National Library of Medicine. NCT04865679 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.